De Giorgi (Takeda), ‘50% of drugs in development will have orphan designation’
"In rare diseases Takeda is the protagonist, strongly committed with an already important portfolio at an ...
Read more"In rare diseases Takeda is the protagonist, strongly committed with an already important portfolio at an ...
Read more"In the report presented today, the results show a high availability of orphan drugs on the ...
Read more"There is little recourse to Law 648/96 for rapid access to orphan drugs for pathologies that ...
Read moreSuara.com - The sad fate befell the families and victims of serial killers or serial killer ...
Read more© Ruetir 2023. All Rights Reserved.